In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).

When asked about his experience working with ABL as a contractor of the Science Moving Towards Research Translation and Therapy (SMARTT ) program, Dr. Idell said, “Working with them has been an absolute pleasure. The ABL contact, Eric Fuog, and his team have been very accommodating and communicate regularly, keeping us posted on their progress… We were very pleased to see that ABL is able to scale up from the lab preparations we used to provide the material needed for additional IND-enabling studies.”

The full article can be found here.